SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

SpringWorks Therapeutics, a commercial-stage biopharmaceutical company (Nasdaq: SWTX), will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami, Florida. The company's management will engage in a fireside chat at 2:00 p.m. ET. A live webcast of the event will be accessible via the company's Investors & Media section on their website, with a replay available shortly after the event concludes.

Positive

• Participation in the Goldman Sachs 45th Annual Global Healthcare Conference provides increased visibility and credibility.
• Engagement in a high-profile event may attract potential investors and partnerships.
• The webcast availability allows broader access to the company's presentation, enhancing transparency.

Negative

• No immediate financial or clinical updates were provided in the announcement.
• The announcement does not detail any new developments or significant milestones.
• Potentially high expectations from investors for substantial updates at the event could lead to disappointment if not met.

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 45^th Annual Global Healthcare Conference, taking place in Miami, Florida on Tuesday, June 11, 2024 at 2:00 p.m. ET.

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO^® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations 
Phone: 203-561-1646
Email: kdiamond@springworkstx.com  

Samantha Hilson Sandler 
Senior Director, Investor Relations 
Phone: 203-461-5501 
Email: samantha.sandler@springworkstx.com 

FAQ

When will SpringWorks Therapeutics participate in the Goldman Sachs 45th Annual Global Healthcare Conference?

SpringWorks Therapeutics will participate on June 11, 2024.

What time is SpringWorks Therapeutics' fireside chat at the Goldman Sachs Healthcare Conference?

The fireside chat will take place at 2:00 p.m. ET.

Where can I access the live webcast of SpringWorks Therapeutics' presentation?

The live webcast will be accessible via the Events & Presentations page within the Investors & Media section of SpringWorks Therapeutics' website.

Will there be a replay available for SpringWorks Therapeutics' presentation at the Goldman Sachs Healthcare Conference?

Yes, a replay of the webcast will be available on the company's website for a time following the conference.